Early Response Assessment in Diffuse Large B-Cell Lymphoma (DLCL) Patients by 18-fluoro-2-deoxyglycose Positron Emission Tomography (FDG-PET)

Completed

Conditions studied: Diffuse Large B-cell Lymphoma

In brief

Newly diagnosed DLCL patients will have baselne FDG-PET as part of initial staging (PET-1). Patients will then undergo 2 cycles of chemotherapy with R/CHOP. 14 to 21 days following cycle 2 of R/CHOP, patients will undergo repeat FDG-PET scan (PET-2). They will then complete therapy as planned. Following completion of therapy, standard response assessment will be performed, including CT scans of the chest, abdomen and pelvis and FDG-PET scan (PET-3).

Key facts

Study ID

NCT00754117

Run by

Weill Medical College of Cornell University

People needed

8

Starts

2008-05-01

Expected to finish

2012-12-08

Last updated by the study team

2018-05-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must have histologically or cytologically confirmed diagnosis of CD20+ diffuse large B cell lymphoma (LBCL) of any stage, including subtypes mediastinal large B cell, centroblastic, immunoblastic, T cell rich B cell and anaplastic B cell lymphoma
• Patients must have received no prior anti-lymphoma therapy.
• Age >18 years.
• Patients must have a treatment plan to include R/CHOP or R/CHOP followed by radiotherapy.
• Ability to understand and the willingness to sign a written informed consent document.

You may not qualify if…

• Patients who have known HIV infection.
• Patients who are, in the opinion of their treating oncologist, unable to undergo R/CHOP chemotherapy.

Where it is running

• Weill Cornell Medical College — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.